Artificial biocornea material is derived from fishscale

Article

Scientists in The Netherlands have received an innovation grant to finalise the specification of a collagen, derived from fishscale, which will act as an alternative material for cornea regeneration.

Scientists in The Netherlands have received an innovation grant to finalise the specification of a collagen, derived from fishscale, which will act as an alternative material for cornea regeneration.

The Department of Ophthalmology of the Leids Universitair Medisch Centrum (LUMC) and Aeon Astron Europe BV (AAE) have officially joined forces to develop the artificial biocornea.

Julio Lin and his team in Taiwan, developed a fishscale-derived collagen scaffold as an alternative material for corneal regeneration. AAE will conduct further research to finalize the specification of the artificial biocornea under supervision of Dr J. Martine Jager, M.D., PhD., former ARVO President, and Prof Dr. G.P.M. Luyten, Head of the Ophthalmology Department of the LUMC.

AAE will transfer the technology and knowledge of the biodegradable biocornea to the LUMC. Michael Lai, CEO, says that AAE has experience in coordinating with the ophthalmologist opinion leaders worldwide and this bio-artificial cornea is the second ophthalmic product AAE is working on.

The LUMC team will undertake the efficacy evaluation in animal models of corneal regeneration and will test the biocompatibility with living cornea cells. The final specification of biocornea will be done through further in vitro and in vivo studies. On completion of the proect it is anticiapted that a human pilot study will get underway. This is a two-year project with a total budget of 1.5 million Euros.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.